Biogen pulls PRIME designation for aducanumab in Europe; Merck closes merger with Acceleron
Following news last week that Biogen received “a negative trend vote” in Europe for its controversial Alzheimer’s drug aducanumab, the EMA updated a list of PRIME designations indicating that some, including Biogen, pulled out of the EU’s priority medicines scheme, known as PRIME.
But Biogen said in a statement to Endpoints News that it actually pulled the PRIME designation for aducanumab in 2019, noting that it occurred “following the discontinuation of the EMERGE and ENGAGE studies,” and that it “was a procedural requirement at the time.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.